Schwab Charles Investment Management Inc. Has $2.99 Million Stake in CryoLife, Inc. (CRY)

Schwab Charles Investment Management Inc. increased its holdings in CryoLife, Inc. (NYSE:CRY) by 30.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 149,791 shares of the medical equipment provider’s stock after buying an additional 35,247 shares during the period. Schwab Charles Investment Management Inc. owned 0.45% of CryoLife worth $2,989,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. State of Alaska Department of Revenue raised its position in shares of CryoLife by 80.8% in the second quarter. State of Alaska Department of Revenue now owns 5,387 shares of the medical equipment provider’s stock valued at $107,000 after buying an additional 2,407 shares in the last quarter. Municipal Employees Retirement System of Michigan raised its position in shares of CryoLife by 3.2% in the first quarter. Municipal Employees Retirement System of Michigan now owns 6,150 shares of the medical equipment provider’s stock valued at $102,000 after buying an additional 190 shares in the last quarter. Mason Street Advisors LLC raised its position in shares of CryoLife by 7.4% in the first quarter. Mason Street Advisors LLC now owns 6,324 shares of the medical equipment provider’s stock valued at $105,000 after buying an additional 438 shares in the last quarter. Creative Planning raised its position in shares of CryoLife by 3.0% in the second quarter. Creative Planning now owns 6,806 shares of the medical equipment provider’s stock valued at $136,000 after buying an additional 200 shares in the last quarter. Finally, Karp Capital Management Corp acquired a new stake in shares of CryoLife in the first quarter valued at approximately $172,000. Institutional investors own 68.36% of the company’s stock.

CryoLife, Inc. (CRY) opened at 20.40 on Friday. The firm has a market capitalization of $682.30 million, a P/E ratio of 61.82 and a beta of 0.92. The firm’s 50-day moving average is $22.04 and its 200 day moving average is $19.36. CryoLife, Inc. has a 12 month low of $14.02 and a 12 month high of $24.00.

CryoLife (NYSE:CRY) last announced its quarterly earnings results on Monday, July 24th. The medical equipment provider reported $0.12 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.10 by $0.02. CryoLife had a net margin of 6.16% and a return on equity of 7.41%. The firm had revenue of $47.80 million during the quarter, compared to the consensus estimate of $47.02 million. During the same period last year, the firm earned $0.13 EPS. The business’s quarterly revenue was up 1.5% compared to the same quarter last year. On average, analysts expect that CryoLife, Inc. will post $0.42 EPS for the current fiscal year.

In other CryoLife news, CEO James P. Mackin sold 125,000 shares of the firm’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $22.01, for a total value of $2,751,250.00. Following the completion of the transaction, the chief executive officer now directly owns 398,399 shares of the company’s stock, valued at approximately $8,768,761.99. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO James P. Mackin sold 43,050 shares of the firm’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $22.09, for a total transaction of $950,974.50. Following the completion of the transaction, the chief executive officer now directly owns 398,399 shares of the company’s stock, valued at $8,800,633.91. The disclosure for this sale can be found here. Over the last three months, insiders sold 171,050 shares of company stock valued at $3,769,825. Insiders own 6.00% of the company’s stock.

A number of equities research analysts have recently weighed in on CRY shares. Canaccord Genuity reiterated a “buy” rating and issued a $25.00 price target on shares of CryoLife in a research report on Monday, October 9th. Zacks Investment Research downgraded shares of CryoLife from a “hold” rating to a “sell” rating in a research report on Tuesday. Lake Street Capital boosted their price objective on shares of CryoLife to $26.00 and gave the company a “buy” rating in a research report on Wednesday, October 11th. Finally, BidaskClub downgraded shares of CryoLife from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $23.63.

WARNING: “Schwab Charles Investment Management Inc. Has $2.99 Million Stake in CryoLife, Inc. (CRY)” was posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.com-unik.info/2017/10/21/schwab-charles-investment-management-inc-has-2-99-million-stake-in-cryolife-inc-cry.html.

CryoLife Company Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Institutional Ownership by Quarter for CryoLife (NYSE:CRY)

What are top analysts saying about CryoLife Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CryoLife Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit